Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Analysis of Short-term (Operating) Activity Ratios

Microsoft Excel

Short-term Activity Ratios (Summary)

Turnover Ratios

Average No. Days

Allergan PLC, short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Turnover Ratios
Inventory turnover 2.20 2.59 2.40 2.59 4.76
Receivables turnover 5.04 5.50 5.50 5.76 6.28
Payables turnover 6.39 6.26 6.68 8.27 13.02
Working capital turnover 287.30 21.12 10.43 1.46 52.49
Average No. Days
Average inventory processing period 166 141 152 141 77
Add: Average receivable collection period 72 66 66 63 58
Operating cycle 238 207 218 204 135
Less: Average payables payment period 57 58 55 44 28
Cash conversion cycle 181 149 163 160 107

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).


The analysis of short-term operating activity ratios reveals a general decline in operational efficiency and an extension of the cash cycle between 2015 and 2019. There is a consistent trend toward slower asset turnover and a corresponding increase in the number of days required to convert inventory and receivables into cash.

Inventory Management
A significant deterioration in inventory efficiency is observed. The inventory turnover ratio declined from 4.76 in 2015 to 2.20 in 2019. Consequently, the average inventory processing period more than doubled, increasing from 77 days to 166 days over the five-year period, indicating a slower movement of goods.
Receivables Management
The efficiency of credit collection shows a gradual downward trend. Receivables turnover decreased from 6.28 in 2015 to 5.04 in 2019. This is reflected in the average receivable collection period, which expanded from 58 days to 72 days, suggesting a slower recovery of funds from customers.
Payables Management
There is a notable shift in the management of obligations to suppliers. The payables turnover ratio fell sharply from 13.02 in 2015 to 6.39 in 2019. This correlates with an increase in the average payables payment period, which rose from 28 days to 57 days, indicating that the company is extending its payment terms to suppliers.
Operating and Cash Conversion Cycles
The combined effect of slower inventory movement and slower collections has led to an extension of the operating cycle, which grew from 135 days in 2015 to 238 days in 2019. While the extension of payables provided a partial offset, the cash conversion cycle still increased from 107 days to 181 days, signifying a greater requirement for working capital to support operations.
Working Capital Turnover
Extreme volatility is present in the working capital turnover ratio. After a sharp decline from 52.49 in 2015 to 1.46 in 2016, the ratio exhibited a strong upward trend, reaching an outlier peak of 287.30 by 2019. This suggests substantial fluctuations in the net working capital balance relative to revenue.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Inventory Turnover

Allergan PLC, inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights 2,493,100 2,191,400 2,168,000 1,860,800 4,810,400
Inventories 1,133,100 846,900 904,500 718,000 1,009,700
Short-term Activity Ratio
Inventory turnover1 2.20 2.59 2.40 2.59 4.76
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Inventory turnover = Cost of sales, excludes amortization and impairment of acquired intangibles including product rights ÷ Inventories
= 2,493,100 ÷ 1,133,100 = 2.20

2 Click competitor name to see calculations.


The inventory turnover ratio experienced a significant contraction between 2015 and 2019, indicating a slowdown in the rate at which inventory was converted into sales. The ratio peaked in 2015 at 4.76 and declined sharply to 2.59 by 2016, eventually reaching a five-year low of 2.20 by the end of 2019.

Inventory Turnover Ratio
A pronounced downward trend is observed, with the turnover rate decreasing by approximately 53.8% over the analyzed period. While a period of relative stabilization occurred between 2016 and 2018, where the ratio fluctuated between 2.40 and 2.59, the final period showed a further decline to 2.20, suggesting a decrease in operational efficiency regarding inventory liquidation.
Cost of Sales Dynamics
Cost of sales, excluding amortization and impairment of acquired intangibles, showed a substantial reduction from 4,810,400 thousand USD in 2015 to 1,860,800 thousand USD in 2016. From 2016 onward, a consistent upward trajectory was observed, with costs rising to 2,493,100 thousand USD by 2019. Despite this gradual increase in sales costs, the growth was insufficient to offset the increase in inventory holdings to maintain previous turnover levels.
Inventory Asset Management
Inventory balances decreased from 1,009,700 thousand USD in 2015 to 718,000 thousand USD in 2016. Subsequently, inventory levels grew steadily, peaking at 1,133,100 thousand USD in 2019. The accumulation of inventory assets, particularly between 2018 and 2019, directly contributed to the compression of the turnover ratio, as the growth in inventory exceeded the growth in the cost of goods sold.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Receivables Turnover

Allergan PLC, receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Net revenues 16,088,900 15,787,400 15,940,700 14,570,600 15,071,000
Accounts receivable, net 3,192,300 2,868,100 2,899,000 2,531,000 2,401,600
Short-term Activity Ratio
Receivables turnover1 5.04 5.50 5.50 5.76 6.28
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Receivables turnover = Net revenues ÷ Accounts receivable, net
= 16,088,900 ÷ 3,192,300 = 5.04

2 Click competitor name to see calculations.


An analysis of operational efficiency regarding credit management reveals a consistent decline in the speed of receivables collection between 2015 and 2019. While net revenues remained relatively stable, the balance of outstanding receivables grew at a faster rate, resulting in a diminished turnover ratio.

Net Revenue Trends
Net revenues exhibited minor fluctuations over the five-year period, starting at 15,071,000 thousand US dollars in 2015 and reaching 16,088,900 thousand US dollars by 2019. Despite a moderate decrease in 2016, the overall revenue trajectory remained consistent, indicating a stable volume of sales activity.
Accounts Receivable Growth
A steady increase is observed in net accounts receivable, which rose from 2,401,600 thousand US dollars in 2015 to 3,192,300 thousand US dollars in 2019. This upward trend signifies that a larger portion of the company's revenue is tied up in unpaid customer invoices at the end of each fiscal year.
Receivables Turnover Analysis
The receivables turnover ratio demonstrates a clear downward trend, decreasing from 6.28 in 2015 to 5.04 in 2019. This decline indicates a reduction in the efficiency of the collection process, meaning the company is taking longer to convert its receivables into cash. The ratio remained stagnant at 5.50 during 2017 and 2018 before declining further in 2019, which may suggest a shift in credit policies or a decrease in the promptness of customer payments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Payables Turnover

Allergan PLC, payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights 2,493,100 2,191,400 2,168,000 1,860,800 4,810,400
Accounts payable 390,400 349,800 324,500 224,900 369,400
Short-term Activity Ratio
Payables turnover1 6.39 6.26 6.68 8.27 13.02
Benchmarks
Payables Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Payables turnover = Cost of sales, excludes amortization and impairment of acquired intangibles including product rights ÷ Accounts payable
= 2,493,100 ÷ 390,400 = 6.39

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a significant shift in the management of accounts payable over the five-year period ending December 31, 2019. The most prominent trend is the substantial decrease in the payables turnover ratio, which indicates a lengthening of the time required to settle obligations with suppliers.

Payables Turnover Ratio Trend
The turnover ratio experienced a sharp decline from 13.02 in 2015 to 8.27 in 2016, continuing a downward trajectory to reach a minimum of 6.26 in 2018. A marginal increase to 6.39 was observed in 2019. This overall downward trend suggests a strategic shift toward extending payment terms, effectively utilizing supplier credit to preserve cash and optimize working capital.
Cost of Sales and Accounts Payable Correlation
Cost of sales exhibited significant volatility, falling from 4.81 billion in 2015 to 1.86 billion in 2016, followed by a steady recovery to 2.49 billion by 2019. Accounts payable followed a similar initial drop in 2016 but grew consistently from 2017 to 2019, rising from 324.5 million to 390.4 million. The ratio's decline was driven by the fact that the growth in accounts payable balances occurred more rapidly than the growth in cost of sales during the later years of the period.
Operational Implications
The reduction in the turnover ratio from 13.02 to 6.39 implies that the company has roughly halved the frequency with which it clears its accounts payable. This suggests an increase in the average payment period, which can improve short-term liquidity but may also indicate a higher reliance on supplier financing to fund operations.

The stabilization of the payables turnover ratio between 2018 and 2019 suggests that the company has established a new baseline for its supplier payment strategy, balancing the benefits of extended credit with the requirements of maintaining healthy vendor relationships.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Working Capital Turnover

Allergan PLC, working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Current assets 11,126,700 6,475,400 11,376,700 17,857,900 8,615,400
Less: Current liabilities 11,070,700 5,727,900 9,848,100 7,874,700 8,328,300
Working capital 56,000 747,500 1,528,600 9,983,200 287,100
 
Net revenues 16,088,900 15,787,400 15,940,700 14,570,600 15,071,000
Short-term Activity Ratio
Working capital turnover1 287.30 21.12 10.43 1.46 52.49
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Working capital turnover = Net revenues ÷ Working capital
= 16,088,900 ÷ 56,000 = 287.30

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a period of significant volatility in working capital management against a backdrop of stable revenue generation. While net revenues remained consistent, fluctuating within a narrow band between 14.57 billion and 16.09 billion US dollars from 2015 to 2019, the working capital balance experienced extreme oscillations that directly impacted operational efficiency ratios.

Net Revenue Stability
Net revenues exhibited a steady trend throughout the observed period, with a slight overall increase from 15.07 billion US dollars in 2015 to 16.09 billion US dollars in 2019. This stability indicates a consistent demand for products and a predictable top-line performance.
Working Capital Volatility
A substantial increase in working capital was observed in 2016, where the balance peaked at 9.98 billion US dollars. Following this spike, a consistent and rapid downward trend occurred, with working capital falling to 1.53 billion US dollars in 2017, 747.5 million US dollars in 2018, and reaching a low of 56 million US dollars by the end of 2019.
Working Capital Turnover Ratio Dynamics
The working capital turnover ratio demonstrated an inverse relationship with the working capital balance. The ratio dropped sharply from 52.49 in 2015 to 1.46 in 2016, coinciding with the surge in working capital. Subsequently, the ratio rose aggressively as working capital contracted, accelerating from 10.43 in 2017 to 21.12 in 2018, and culminating in an extreme value of 287.30 in 2019.
Operational Implications
The dramatic rise in the turnover ratio toward 2019 suggests an increasingly lean approach to managing current assets and liabilities. While a higher ratio typically indicates greater efficiency in utilizing working capital to generate sales, the precipitous decline in the absolute value of working capital to 56 million US dollars by 2019 may indicate a highly aggressive liquidity position.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Average Inventory Processing Period

Allergan PLC, average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Inventory turnover 2.20 2.59 2.40 2.59 4.76
Short-term Activity Ratio (no. days)
Average inventory processing period1 166 141 152 141 77
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.20 = 166

2 Click competitor name to see calculations.


An analysis of the short-term activity ratios reveals a significant decline in inventory management efficiency between 2015 and 2019. A sharp shift in operational performance occurred after 2015, characterized by a substantial increase in the time required to convert inventory into sales, which remained elevated through the end of the period.

Inventory Turnover
A marked downward trend is observed in the inventory turnover ratio, which fell from 4.76 in 2015 to 2.20 by 2019. The most precipitous decline occurred between 2015 and 2016, where the ratio dropped by approximately 45%. While the ratio showed a slight recovery in 2018, it ultimately reached its lowest point in 2019, suggesting a reduced velocity of inventory movement.
Average Inventory Processing Period
The average inventory processing period demonstrates an inverse correlation with the turnover ratio, showing a general upward trajectory. The period expanded from 77 days in 2015 to 166 days in 2019, effectively more than doubling the time inventory is held. Following a sharp increase to 141 days in 2016, the period peaked at 152 days in 2017, experienced a temporary contraction to 141 days in 2018, and reached a five-year high in 2019.

The convergence of these trends indicates a systemic slowdown in inventory circulation. The transition from a 77-day processing cycle in 2015 to a 166-day cycle in 2019 suggests either an increase in safety stock levels, a shift in product mix toward slower-moving goods, or a decrease in demand relative to inventory holdings.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Average Receivable Collection Period

Allergan PLC, average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Receivables turnover 5.04 5.50 5.50 5.76 6.28
Short-term Activity Ratio (no. days)
Average receivable collection period1 72 66 66 63 58
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.04 = 72

2 Click competitor name to see calculations.


An analysis of the operating activity ratios from 2015 to 2019 reveals a progressive decline in the efficiency of receivable management and a lengthening of the cash conversion cycle.

Receivables Turnover
The receivables turnover ratio exhibits a consistent downward trajectory, decreasing from 6.28 in 2015 to 5.04 by the end of 2019. While a brief period of stability was observed between 2017 and 2018, where the ratio remained constant at 5.50, the overall trend indicates a reduction in the frequency with which accounts receivable are collected during the annual period.
Average Receivable Collection Period
The average receivable collection period demonstrates a corresponding upward trend, increasing from 58 days in 2015 to 72 days in 2019. This represents a total increase of 14 days over the five-year interval, confirming that a larger proportion of capital is tied up in receivables for longer durations before being converted into cash.

The inverse correlation between the declining turnover ratio and the increasing collection period indicates a deterioration in credit collection efficiency. The transition to a 72-day collection cycle suggests potential shifts in credit policies or a decrease in customer payment punctuality, which may exert pressure on short-term liquidity and increase the company's reliance on other working capital sources.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Operating Cycle

Allergan PLC, operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Average inventory processing period 166 141 152 141 77
Average receivable collection period 72 66 66 63 58
Short-term Activity Ratio
Operating cycle1 238 207 218 204 135
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 166 + 72 = 238

2 Click competitor name to see calculations.


The company's operating cycle exhibited a consistent upward trend over the five-year period from 2015 to 2019, indicating a lengthening of the time required to convert investments in inventory and receivables back into cash.

Average Inventory Processing Period
A significant increase is observed in the duration required to process inventory. The period rose sharply from 77 days in 2015 to 141 days in 2016, eventually reaching 166 days by the end of 2019. This upward trajectory suggests a deceleration in inventory turnover, which may be attributed to increased stockpiling or a slower sales velocity relative to the volume of inventory held.
Average Receivable Collection Period
The time taken to collect payments from customers demonstrates a gradual and steady increase. Starting at 58 days in 2015, the collection period climbed to 72 days by 2019. Although this trend is less volatile than the changes seen in inventory processing, the consistent rise indicates a slight decrease in the efficiency of credit and collection management.
Operating Cycle
The total operating cycle expanded from 135 days in 2015 to 238 days in 2019. This extension is primarily driven by the substantial increase in the inventory processing period, with the receivable collection period contributing a secondary, smaller impact. The overall expansion of the cycle by 103 days suggests a heightened reliance on working capital to sustain operational activities.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Average Payables Payment Period

Allergan PLC, average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Payables turnover 6.39 6.26 6.68 8.27 13.02
Short-term Activity Ratio (no. days)
Average payables payment period1 57 58 55 44 28
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 6.39 = 57

2 Click competitor name to see calculations.


An examination of the short-term activity ratios reveals a significant shift in the management of accounts payable between 2015 and 2019. There is a pronounced trend toward extending the duration of payments to suppliers, resulting in a lower turnover rate and a longer payment cycle.

Payables Turnover
A consistent decline in the turnover ratio is observed from 2015 to 2018, falling from 13.02 to 6.26. This indicates a reduction in the frequency with which obligations are settled. The ratio stabilized in 2019 at 6.39, suggesting that the pace of payable turnover has reached a plateau.
Average Payables Payment Period
The average time taken to pay suppliers increased significantly, rising from 28 days in 2015 to a peak of 58 days in 2018. This represents a growth of approximately 107% in the payment window over a three-year span. By 2019, the period remained relatively constant at 57 days.
Working Capital Implications
The inverse relationship between the declining turnover ratio and the increasing payment period demonstrates a shift in liquidity management. By extending the payment duration, the organization retains cash for longer periods, which enhances short-term cash flow and suggests a strategy to optimize working capital by leveraging supplier credit.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Cash Conversion Cycle

Allergan PLC, cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Average inventory processing period 166 141 152 141 77
Average receivable collection period 72 66 66 63 58
Average payables payment period 57 58 55 44 28
Short-term Activity Ratio
Cash conversion cycle1 181 149 163 160 107
Benchmarks
Cash Conversion Cycle, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 2019 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 166 + 72 – 57 = 181

2 Click competitor name to see calculations.


The cash conversion cycle exhibited a significant overall expansion between 2015 and 2019, increasing from 107 days to 181 days. This indicates a general lengthening of the time required to convert resource inputs into cash flows from sales, reflecting an increase in working capital requirements over the five-year period.

Average Inventory Processing Period
The most substantial driver of the extended cash conversion cycle is the inventory processing period, which rose from 77 days in 2015 to 166 days in 2019. Despite a moderate decrease to 141 days in 2018, the long-term trend shows a marked slowing in inventory turnover, more than doubling over the analyzed timeframe.
Average Receivable Collection Period
A steady upward trend is observed in the receivable collection period, moving from 58 days in 2015 to 72 days by 2019. This gradual increase suggests a decline in the efficiency of credit collections or a strategic shift in payment terms granted to customers.
Average Payables Payment Period
The payables payment period increased consistently from 28 days in 2015 to a peak of 58 days in 2018, ending at 57 days in 2019. This extension in payment timing serves as a partial offset to the delays in inventory turnover and receivable collections, effectively preserving cash by delaying outflows to suppliers.
Net Cash Conversion Cycle Trend
The cumulative effect of these components resulted in a cycle that grew by 74 days over five years. The temporary reduction in the cycle observed in 2018 was primarily attributable to a decrease in the inventory processing period, though this improvement was reversed by 2019, leading to the period's peak of 181 days.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?